Flagstar Bank NA vs Halozyme Therapeutics Inc. Common Stock — how do they compare? Flagstar Bank NA trades at $11.32 (market cap $4.71B), while Halozyme Therapeutics Inc. Common Stock trades at $110.42 (market cap $12.58B). The key difference: Halozyme Therapeutics Inc. Common Stock is far larger — about 2.7× Flagstar Bank NA's market cap, and Flagstar Bank NA pays a 0.35% dividend while Halozyme Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Flagstar Bank NA for 22 Days and Halozyme Therapeutics Inc. Common Stock for 1 Days on average.
| FLG | HALO | |
|---|---|---|
Market Cap | $4.71B | $12.58B |
Volume | 7,410,589 | 2,179,278 |
Sector | Financials | Health |
52-Week High | $15.36 | $115.22 |
52-Week Low | $10.72 | $61.63 |
Typical Hold Time | 22 Days | 1 Days |
Enterprise Value | $15.25B | $14.49B |
Dividend Yield | 0.35% | — |
Signals from Pluang's Aura AI — not financial advice
FLG trades at $11.35, up 0.44% with a bearish technical signal despite recent earnings beats. The stock shows mixed fundamentals with a high P/E of 378.33 but trades below book value at P/B of 0.62. Recent Q2 2026 earnings missed expectations, though the company announced a $250 million share repurchase program and maintains a dividend. Analyst consensus remains bullish with a $17.07 price target.
FLG presents a turnaround opportunity with improving profitability from 2025 losses to 2026 projected net income of $48 million. Key risks include volatile cash flows and competitive banking pressures. The stock's discount to book value and strong analyst support suggest potential upside if execution improves.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Flagstar Bank is a prominent US financial institution and a subsidiary of New York Community Bancorp. It provides commercial banking, mortgage services, and diverse personal finance products.
Read more on FLG →Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →